We investigated the capacity of 3 major cytokines secreted by activated monocytes, IL-1 p, TNFa and IL-6, to inhibit growth of melanoma tumor cells. Using neutralizing antibodies against IL-lp, TNFtt and IL-6, we observed that the cytostatic activity against A375 melanoma cells is largely due to the presence of IL-6 in culture supernatants of monocytes stimulated with LPS. A375 cells appeared to be extremely sensitive to monocytederived cytokines, since in addition to rlL-6 also rIL-lp and rTNFtt displayed cytostatic activity against A375 cells. We observed additive or synergistic cytostatic effects upon use of combinations of these cytokines. When 7 other melanoma cell lines and short-term melanoma cultures were tested and compared with A375, a major difference in their sensitivity to monocyte-derived cytokines were observed. Although 7 out of 8 melanoma cell lines were sensitive to culture supernatants of monocytes stimulated with LPS, significant differences were found when recombinant cytokines were used. The widely used A375 was the only melanoma cell line sensitive to rIL-Ip, rTNFa and rlL-6. The growth of none of the other 7 melanoma cell cultures was significantly affected by rIL-lp. Seven out of 8 melanoma cell cultures were sensitive to rTNFa and 3 out of 8 to rlL-6. The results of our study indicate that the sensitivity of melanoma cell cultures for different monocyte-derived cyto kines is highly variable, and that it is questionable whether the A375 melanoma cell line, sensitive to rIL-1 p, rTNFa and rlL-6, is representative for melanoma.
Monocytes activated by LPS produce a number of cytokines with cytostatic activity for certain tumor cells. Dependent on the target cells used to measure anti-tumor cytostatic/cytotoxic activity of monocytes, various studies report that this effect must be ascribed to IL-1(B and TNFa secreted by monocytes (Onozaki et al, 1985; Ruggiero and Baglioni, 1987) . If human A375 melanoma cells are used as target cells, both monokines, either alone or in combination, have been shown to possess potential anti-tumor effects (Ruggiero and Baglioni, 1987; Ichinose et al, 1988; Nakai et al, 1988) . However, with the availability of recombinant cytokines, data are accumulating that many of the activities that were formerly ascribed to purified IL-1 preparations may be mediated by other contami nating cytokines present in the purified material (Wong and Clark, 1988; Helle et a l , 19886). Furthermore, the biological assays by which the IL-1 activity was determined were also found to be sensitive for TN Fa and IL-6 (Wong and Clark, 1988; Van Damme et al, 1988) . In addition, IL-1 can induce the production of IL-6 in monocytes (Tosato and Jones, 1990) and IL-1 and TNF can induce each other's release by mono cytes (Dinarello et a l, 1986). These observations prompted us to investigate the cytostatic activity of monocyte-derived IL-6.
Our results demonstrate that not IL-lp and/or T N Fa but IL-6 is the major cytokine with cytostatic activity against A375 melanoma cells present in monocyte culture supernatant. However, the sensitivity of different melanoma cell lines to these 3 cytokines was highly variable.
MATERIAL AND METHODS

Monocytes and monocyte culture
Human peripheral-blood monocytes were isolated and cul tured as described by TNFa in the culture supernatant of human monocytes was tested using the Biokine TNF Test Kit (T-cell Sciences, Cambridge, MA). The sensitivity of this assay is 10 pg TNFa/m! and no detectable cross-reactivity with other de scribed cytokines can be observed.
IL-6 in the culture supernatant of human monocytes was tested using the R and D Systems Quantikine human IL-6 immunoassay (Minneapolis, MN). The sensitivity of this assay is 3.5 pg/ml and it shows no detectable cross-reactivity with other known cytokines.
Growth inhibition assay
Melanoma cells Table I . To investigate whether IL -lp, T N Fa and/or IL-6 were responsible for the cytostatic activity found in culture supernatant of LPS-activated monocytes, we per formed blocking experiments with antibodies in saturating concentrations that neutralized cytokine activity. Figure la shows a dose-response curve of the growth-inhibitory effect of monocyte culture supernatant on the melanoma cell line A375. The results indicate that 5% culture supernatant causes maximal growth inhibition. MAbs against IL -lp did not neutralize the cytostatic activity present in high concentrations in the monocyte supernatants (Fig. lb) . Also anti-TNFa MAb alone did not cause significant reduction of maximal cytostatic activity. Since IL-lp and T N F a can act synergistically on several tumor cell lines (Ruggiero and Baglioni, 1987), we studied the effect of combinations of anti-IL-l(3 MAb with anti-TNFa MAb (Fig. lc ) . However, no additional blocking of the cytostatic activity by either anti-IL-1 p or anti-TNFa was observed. Only at dilutions of the monocyte supernatant of 1:100 to 1:500 could a 50% reduction of the inhibition of cytostatic activity be observed with anti-IL-lp and/or antiTNFa antibodies (Fig. 1, b, c can induce IL-6 activity (Tosato and Jones, 1990), we tested the effect of anti-IL-6 antibodies on the cytostatic capacity of LPS-activated monocyte culture supernatants. As shown in Figure Id , addition of anti-IL-6 antibodies almost completely abrogates the growth-inhibitory capacity of the monocyte supernatant. Combination of anti-IL-6 MAb with anti-IL-lp MAb and/or anti-TNFa MAb did not cause additional effects (Fig. le, ƒ) . Anti-IL-lp and/or anti-TNFa cause a 50% reduction of the cytostatic activity in the presence of low concentrations of IL-6, indicating that IL -lp and/or TN Fa have synergistic or additive effects on the cytostatic activity at low concentrations of IL-6.
Taken together, our results indicate that IL -lp and/or TNFa are not the factors in activated monocyte supernatants that are responsible for cytostatic effects against human A375 cells, but that IL-6 appears to be the major cytokine with cytostatic activity against A375 cells produced by activated monocytes.
The finding that IL-6 is the major cytokine with cytostatic activity in monocyte culture supernatant does not exclude IL-lp and/or TNFa possessing cytostatic activity. To investi gate whether IL-lp and/or T N Fa have cytostatic activity against the human melanoma cell line A375> w e performed a growth-inhibition assay with recombinant cytokines. The re sults (Fig. 2) In conclusion, our data indicate that IL-6 is the main factor in mediating monocyte cytostatic activity against A375 mela noma cells.
Additive and synergistic effects o frIL -I p, rTNFa and rIL-6
The data shown in Figure 1 (b and c) suggest that low concentrations of IL-lp, TNFa and IL-6, IL-lp and/or TN Fa present in diluted monocyte supernatants can exert synergistic or additive effects with IL-6 on the growth of the A375 melanoma cell line. Therefore we investigated mixtures of low doses of rIL-lp and rTNFa, rIL-lp and rIL-6, and rTNFa and rIL-6 in a growth-inhibition assay using A375 cells. Additive or sometimes synergistic effects can be observed if rIL-ip and rTNFa are combined (Fig. 3a) . However, much higher antitumor activity was observed when IL~ip and IL-6 were combined (Fig. 3b) . True synergistic effects were measured when IL-6 was combined with low concentrations of T N Fa (Fig. 3c) . Concentrations of IL-1 (3 and TNFa, which by themselves have low cytostatic activity on A375 cells, are effective if combined with low concentrations of IL-6. These results indicate that low concentrations of IL-ip, TN Fa and IL-6 administered together have additive or synergistic effects on the growth of A375 cells.
Effect of IL-1 p, TNFa and IL-6 on melanoma cells other than A375
A375 melanoma cells are extremely sensitive to monocytederived cytostatic factors and this cell line is the most com monly used target in these assays (Ruggiero and Baglioni, 1987; Ichinose et al, 1988; Nakai et ai, 1988) . We were interested to determine whether other melanoma cell lines were sensitive to monocyte-derived cytokines, and especially if these cells were also sensitive to IL-6. The cytostatic effect of monocyte supernatant (after 4 hr incubation with LPS) was compared with that of recombinant IL -lp s TNFa, IL-6 and GM-CSF and tested on 4 different melanoma cell lines (Fig.  4) . A375 and M14 are equally sensitive to cytostatic factors present in the monocyte culture supernatant, followed by Mel 518 A2 and MeWo, which appear to be insensitive to factors present in this supernatant. Exposure of the melanoma cells to the different recombinant monokines showed that only A375 cells are sensitive to rIL-ip, whereas A375, M14 and Mel 518 A2 are sensitive to rTNFa (Fig. 4) . The growth of MeWo, which is not sensitive to monocyte-supernatant-derived fac tors, is affected neither by rTNFa nor by IL-1 (3, IL-6 affects the growth of both A375 and M14, although the latter is less sensitive. MeWo and Mel 518 A2 are relatively insensitive to rIL-6. rGM-CSF has no significant effect on the growth of any of the melanoma cell lines tested (Fig. 4) . Table II shows the comparison of the A375 melanoma cell line with a cell line derived from a primary melanoma lesion and 3 short-term cultures ( < 2-month culture) of a metastatic melanoma lesion. Despite the low proliferative capacity exhibited by the short term cultures, we found that these cultures also display variability in sensitivity to cytokines.
From these data we conclude that, as illustrated by this randomly chosen panel of melanoma cell lines and short-term cultures, the sensitivity of melanoma cells for monocytederived factors is highly variable. 
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TE VELDE ET AL. 'Melanoma cultures were incubated with 3H-tliymidine for 4 hr after culture for 72 hr in the presence of various cytokines or monocyte culture supernatant (mo-sup),-2The following cytokines are used; 20% mo-sup, 100 U/ml of rIL-lp, 10,000 U of rTNFa, 10,000 U of rIL-6 or 5%/ml of rGM-CSF cos cell culture supernatant.-^The data are presented as % growth inhibition. The growth-inhibition assay was performed as described in the text.
TABLE II -COM PARISON OF TH E EFFEC T O F M ONOKINES ON T H E G R O W T H O F A M ELA N O M A C ELL LIN E D E R IV E D FROM A PRIM ARY M ELANOM A LESIO N AND 3 D IF F E R E N T PR IM A R Y C U LTU R ES O F A M ETASTATIC M ELANOM A LESION W ITH T H E A375 M ELA N O M A CELL LINE
part of the reported cytostatic activity ascribed to IL-1 must be attributed to TN Fa and IL-6.
When the contribution of different cytostatic factors present in monocyte supernatant was compared with single and com bined recombinant factors a discrepancy was observed ( Figs,  1-3) . In principle, cytokines present in monocyte culture supernatants should not behave differently from recombinant cytokines. However, the ultimate growth-inhibitory capacity of a monocyte culture supernatant is an end result of both inhibitory and stimulatory activities. The inability of anti-IL-lp and anti-TNFa to block monocyte-mediated growth inhibition could not be ascribed to IL-1 (3 and TNFa inactivity caused by inhibitors present in the culture medium, inasmuch as addition of rIL-lp o r rTNFa to the monocyte culture supernatant inhibited tumor growth (results not shown). A possible expla nation for this finding is that, compared with IL-lp and TNFa, monocytes produce much higher levels of IL-6 activity. In Table I it was shown that 5% monocyte supernatant causing maximal growth inhibition (Fig. 1) can produce IL-6 upon treatment with IL-la, the elaborated IL-6 acting as an autocrine inhibitor of cell proliferation, However, IL-6 production was moderate and resulted in a growth inhibition of less than 30%, The finding that melanoma cells secrete IL -la and that IL -la is involved in stimulation of melanoma cell IL-6 production suggests that regulation of cytokine secretion is complex. An important point that re quires further investigation is whether melanoma cells also produce cytokines in vivo or whether the observed capacity to secrete cytokines is acquired by in vitro culturing.
Compared with 3 other melanoma cell lines which are relatively insensitive to one or more of the monocyte-derived cytokines, the A375 melanoma cell line is unique, since it is sensitive to rIL-lp, rTNFa and rIL-6 (Fig. 4) . This cell line is therefore unsuitable for measuring IL-1 activity in a bioassay, as suggested by Nakai et al (1988), since effects of TNFa and IL-6 cannot be excluded. The observed sensitivity for IL-6 appears to be confined to only a few melanoma cell lines: only 3 out of 8 melanoma cultures are more or less sensitive for IL-6. So it is questionable whether the A375 cell line is representative for melanoma in general.
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